Cargando…
Thymoquinone, as a Novel Therapeutic Candidate of Cancers
To date, natural products are widely used as pharmaceutical agents for many human diseases and cancers. One of the most popular natural products that have been studied for anticancer properties is thymoquinone (TQ). As a bioactive compound of Nigella sativa, TQ has shown anticancer activities throug...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074212/ https://www.ncbi.nlm.nih.gov/pubmed/33923474 http://dx.doi.org/10.3390/ph14040369 |
_version_ | 1783684303927902208 |
---|---|
author | Almajali, Belal Al-Jamal, Hamid Ali Nagi Taib, Wan Rohani Wan Ismail, Imilia Johan, Muhammad Farid Doolaanea, Abd Almonem Ibrahim, Wisam Nabeel |
author_facet | Almajali, Belal Al-Jamal, Hamid Ali Nagi Taib, Wan Rohani Wan Ismail, Imilia Johan, Muhammad Farid Doolaanea, Abd Almonem Ibrahim, Wisam Nabeel |
author_sort | Almajali, Belal |
collection | PubMed |
description | To date, natural products are widely used as pharmaceutical agents for many human diseases and cancers. One of the most popular natural products that have been studied for anticancer properties is thymoquinone (TQ). As a bioactive compound of Nigella sativa, TQ has shown anticancer activities through the inhibition of cell proliferation, migration, and invasion. The anticancer efficacy of TQ is being investigated in several human cancers such as pancreatic cancer, breast cancer, colon cancer, hepatic cancer, cervical cancer, and leukemia. Even though TQ induces apoptosis by regulating the expression of pro- apoptotic and anti-apoptotic genes in many cancers, the TQ effect mechanism on such cancers is not yet fully understood. Therefore, the present review has highlighted the TQ effect mechanisms on several signaling pathways and expression of tumor suppressor genes (TSG). Data from relevant published experimental articles on TQ from 2015 to June 2020 were selected by using Google Scholar and PubMed search engines. The present study investigated the effectiveness of TQ alone or in combination with other anticancer therapeutic agents, such as tyrosine kinase inhibitors on cancers, as a future anticancer therapy nominee by using nanotechnology. |
format | Online Article Text |
id | pubmed-8074212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80742122021-04-27 Thymoquinone, as a Novel Therapeutic Candidate of Cancers Almajali, Belal Al-Jamal, Hamid Ali Nagi Taib, Wan Rohani Wan Ismail, Imilia Johan, Muhammad Farid Doolaanea, Abd Almonem Ibrahim, Wisam Nabeel Pharmaceuticals (Basel) Review To date, natural products are widely used as pharmaceutical agents for many human diseases and cancers. One of the most popular natural products that have been studied for anticancer properties is thymoquinone (TQ). As a bioactive compound of Nigella sativa, TQ has shown anticancer activities through the inhibition of cell proliferation, migration, and invasion. The anticancer efficacy of TQ is being investigated in several human cancers such as pancreatic cancer, breast cancer, colon cancer, hepatic cancer, cervical cancer, and leukemia. Even though TQ induces apoptosis by regulating the expression of pro- apoptotic and anti-apoptotic genes in many cancers, the TQ effect mechanism on such cancers is not yet fully understood. Therefore, the present review has highlighted the TQ effect mechanisms on several signaling pathways and expression of tumor suppressor genes (TSG). Data from relevant published experimental articles on TQ from 2015 to June 2020 were selected by using Google Scholar and PubMed search engines. The present study investigated the effectiveness of TQ alone or in combination with other anticancer therapeutic agents, such as tyrosine kinase inhibitors on cancers, as a future anticancer therapy nominee by using nanotechnology. MDPI 2021-04-16 /pmc/articles/PMC8074212/ /pubmed/33923474 http://dx.doi.org/10.3390/ph14040369 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Almajali, Belal Al-Jamal, Hamid Ali Nagi Taib, Wan Rohani Wan Ismail, Imilia Johan, Muhammad Farid Doolaanea, Abd Almonem Ibrahim, Wisam Nabeel Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
title | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
title_full | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
title_fullStr | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
title_full_unstemmed | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
title_short | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
title_sort | thymoquinone, as a novel therapeutic candidate of cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074212/ https://www.ncbi.nlm.nih.gov/pubmed/33923474 http://dx.doi.org/10.3390/ph14040369 |
work_keys_str_mv | AT almajalibelal thymoquinoneasanoveltherapeuticcandidateofcancers AT aljamalhamidalinagi thymoquinoneasanoveltherapeuticcandidateofcancers AT taibwanrohaniwan thymoquinoneasanoveltherapeuticcandidateofcancers AT ismailimilia thymoquinoneasanoveltherapeuticcandidateofcancers AT johanmuhammadfarid thymoquinoneasanoveltherapeuticcandidateofcancers AT doolaaneaabdalmonem thymoquinoneasanoveltherapeuticcandidateofcancers AT ibrahimwisamnabeel thymoquinoneasanoveltherapeuticcandidateofcancers |